Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
Total revenues	$ 4,011,000	$ 3,787,000	$ 10,655,000	$ 8,915,000
Operating expenses:
Cost of sales	1,052,000		1,388,000
Research and development	66,440,000	49,292,000	126,507,000	79,937,000
Selling, general and administrative	40,214,000	20,329,000	71,755,000	35,350,000
Total operating expenses	107,706,000	69,621,000	199,650,000	115,287,000
Loss from operations	(103,695,000)	(65,834,000)	(188,995,000)	(106,372,000)
Interest and other income (expense), net	1,828,000	(124,000)	5,199,000	289,000
Interest expense	(4,104,000)	(3,456,000)	(6,685,000)	(5,095,000)
Net loss	(105,971,000)	(69,414,000)	(190,481,000)	(111,178,000)
Net (income) loss attributable to noncontrolling interest (SRX Cardio)	(223,000)	(240,000)	109,000	(195,000)
Net loss attributable to Portola	$ (106,194,000)	$ (69,654,000)	$ (190,372,000)	$ (111,373,000)
Net loss per share attributable to Portola common stockholders:
Basic and diluted	$ (1.61)	$ (1.22)	$ (2.90)	$ (1.96)
Shares used to compute net loss per share attributable to Portola common stockholders:
Basic and diluted	65,884,767	57,050,523	65,698,391	56,872,644
Product Revenue, Net
Revenues:
Total revenues	$ 2,265,000		$ 2,871,000
Collaboration and License Revenue
Revenues:
Total revenues	$ 1,746,000	$ 3,787,000	$ 7,784,000	$ 8,915,000